Abstract
Each single dose of rivaroxaban was well tolerated, with predictable pharmacokinetics and pharmacodynamics at doses up to 40 mg, and provided effective anticoagulation in healthy elderly subjects. Adverse events were somewhat elevated in the 50 mg group, but given the small sample size, no specific conclusions can be drawn about this dosing level.
Keywords
MedicinePharmacodynamicsPharmacokineticsRivaroxabanPharmacologyIntensive care medicineInternal medicineWarfarinAtrial fibrillation
Affiliated Institutions
Related Publications
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors
Purpose To identify the optimal regimen and dosage of the oral mammalian target of rapamycin inhibitor everolimus (RAD001). Methods We performed a dose-escalation study in advan...
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
A once-daily, 10-mg oral dose of rivaroxaban was significantly more effective for extended thromboprophylaxis than a once-daily, 40-mg subcutaneous dose of enoxaparin in patient...
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
Rivaroxaban offers a simple, single-drug approach to the short-term and continued treatment of venous thrombosis that may improve the benefit-to-risk profile of anticoagulation....
Prevalence of atrial fibrillation and eligibility for anticoagulants in the community
Anticoagulants are effective in the prevention of stroke in atrial fibrillation and flutter (AF). We aimed to find out the prevalence of AF in the UK and to estimate the proport...
Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma
Purpose The primary objective of this phase I/II study was to determine the safety and pharmacokinetic profile of either transfectoma- or a hybridoma-derived ipilimumab. Seconda...
Publication Info
- Year
- 2008
- Type
- article
- Volume
- 24
- Issue
- 10
- Pages
- 2757-2765
- Citations
- 270
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
270
OpenAlex
Cite This
Dagmar Kubitza,
Michael Becka,
Angelika Roth
et al.
(2008).
Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects.
Current Medical Research and Opinion
, 24
(10)
, 2757-2765.
https://doi.org/10.1185/03007990802361499
Identifiers
- DOI
- 10.1185/03007990802361499